Leading SARS-CoV-2 antibody tests meet specificity but fail current sensitivity guidelines
10 July 2020. Related: COID-19: DIAGNOSTICS, Early access, COVID-19.
Early access
Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study
9 July 2020. Related: Early access, Conference reports, Pregnancy.
HepC drugs work against COVID-19: faster recovery and reduced mortality from generic sofosbuvir and daclatasvir
9 July 2020. Related: Early access, Conference reports, COVID-19: INVESTIGATIONAL DRUGS, COVID-19.
New HIV remission case report at AIDS 2020: full report
8 July 2020. Related: Early access, Conference reports, Cure research.
AIDS2020 online: introduction
8 July 2020. Related: Early access, Conference reports.
Case report of short-term HIV remission from adding oral nicotinamide to intensified ART
7 July 2020. Related: Early access, Conference reports.
Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS
7 July 2020. Related: Early access.
Individualising management of COVID-19 based on real-time inflammatory responses
5 July 2020. Related: Early access, COVID-19: INVESTIGATIONAL DRUGS, COVID-19.
Pneumocystis Jirovecii Pneumonia (PJP) mistaken for COVID-19 in late stage undiagnosed: urgency of including HIV testing on admission
5 July 2020. Related: Early access, COVID-19: HIV and COVID-19 coinfection, COVID-19.
Hydroxychloroquine and lopinavir/r arms stopped in the WHO SOLIDARITY study
5 July 2020. Related: Early access, COVID-19: INVESTIGATIONAL DRUGS, COVID-19.
FDA approves fostemsavir for multidrug resistant HIV in the US
2 July 2020. Related: Early access, Antiretrovirals.
RECOVERY study reports that lopinavir/r fails to show benefit against COVID-19
2 July 2020. Related: Early access, COVID-19: INVESTIGATIONAL DRUGS, COVID-19.
EMA grants conditional approval for remdesivir in the EU to treat COVID-19
2 July 2020. Related: Early access, COVID-19: INVESTIGATIONAL DRUGS, COVID-19.
FDA guidance on COVID-19 vaccine includes minimal target of 50% efficacy
2 July 2020. Related: Early access, COVID-19: VACCINE, COVID-19.
HTB 30 September 2019 online
30 September 2019. Related: Editorial, Early access.
29 March 2019: vol 20 no 4 – second CROI reports
28 March 2019. Related: Editorial, Early access.